Drug release mechanisms of chemically cross-linked albumin microparticles: effect of the matrix erosion.

Albumin (BSA) microparticles were developed as a biotechnological alternative for drug delivery. Vitamin B12 (Vit-B12) was used as a model drug. The microparticles were obtained from maleic anhydride-functionalized BSA and N',N'-dimethylacrylamide (DMAAm) in a W/O emulsion without and with PVA.

Covalent TiO(2)/pectin microspheres with Fe(3)O(4) nanoparticles for magnetic field-modulated drug delivery.

Covalent TiO(2)-co-pectin microspheres containing Fe(3)O(4) nanoparticles were developed through an ultrasound-induced crosslinking/polymerization reaction between the glycidyl methacrylate from vinyl groups in TiO(2) and in pectin. ζ-potentials became less negative in the nanostructured microspheres, caused by the presence of both inorganic particles in the negatively charged pectin. The nanostructured pectin microspheres showed an amoxicillin release rate slower than that of pure pectin microspheres.

Covalent albumin microparticles as an adjuvant for production of mucosal vaccines against hepatitis B.

Covalently modified albumin (BSA) microparticles were developed for potential use as an adjuvant in mucosal vaccines against hepatitis B. To synthesize consistent protein particles, a covalent approach was proposed to modify BSA. Our strategy was to bond maleic anhydride (MA) molecules to BSA structure by nucleophilic reaction for further radical cross-linking/polymerization reaction with N',N'-dimethylacrylamide (DMAAm).